Company Overview
Mangalam Drugs and Organics Limited reported severe financial deterioration in FY26, with consolidated net loss of ₹44.40 crore compared to a profit of ₹6.72 crore in FY25, representing one of the most challenging periods in the company's 50-year history.
Financial Performance
Revenue declined 27% to ₹232.13 crore from ₹317.58 crore in FY25, primarily due to disruptions in global health agency funding (Global Fund, UNICEF, UNITAID, USAID) which accounts for 65-70% of revenue. The withdrawal of USAID funding in December 2025 and geopolitical factors caused order deferrals and reduced tender participation. Key financial ratios deteriorated significantly: debt-equity ratio worsened to 1.09 from 0.65, current ratio fell to 0.79 from 1.04, and return on net worth turned negative at -0.35 from 0.05.
Defaults and Financial Stress
The company defaulted on multiple loan repayments to banks and financial institutions including State Bank of India (₹112.87 lakhs principal + interest), Bank of Maharashtra (₹27.03 lakhs), Bank of Baroda (₹67.30 lakhs), and several NBFCs. Cash reserves dwindled to ₹7.01 lakhs from ₹25.89 lakhs in FY25, while total borrowings increased to ₹102.06 crore from ₹80.19 crore.
Corporate Actions and Governance
The 53rd AGM is scheduled for September 23, 2026, with proposals to appoint S.N. Nanda & Co. as statutory auditors and L.N. Joshi & Co. as secretarial auditors. The board approved a merger scheme with Mangalam Laboratories and Shri JB Pharma, which received NOC from BSE and NSE and shareholder approval, pending NCLT hearing on June 2, 2026. Management changes included appointment of Jeevan Dalvi as CFO and Shweta Patel as Company Secretary.
Regulatory Compliance and Disclosures
The annual report includes comprehensive disclosures of material related party transactions requiring shareholder approval, audit qualifications in CARO report regarding borrowing defaults, and non-compliances with SEBI LODR regulations including inadequate board composition and delayed filings. The company disclosed contingent liabilities of ₹2.20 lakhs and bank guarantees of ₹193.43 lakhs.
Recovery Initiatives and Outlook
Management implemented cost rationalization, working capital improvements, workforce optimization, and product portfolio realignment. However, the company faces significant challenges from ongoing funding disruptions, high debt burden, and operational constraints, with recovery dependent on restoration of international donor funding and successful execution of the merger scheme.